<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04487249</url>
  </required_header>
  <id_info>
    <org_study_id>20-08</org_study_id>
    <nct_id>NCT04487249</nct_id>
  </id_info>
  <brief_title>Trial of Vision Therapy for Intermittent Exotropia</brief_title>
  <acronym>VT-IXT</acronym>
  <official_title>A Pilot Randomized Trial Evaluating Short-Term Effectiveness of Vision Therapy in Children With Intermittent Exotropia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Southern California College of Optometry at Marshall B. Ketchum University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Stanford University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Ohio State University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Salus University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Alabama at Birmingham</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Southern College of Optometry</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Case Western Reserve University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>American Academy of Optometry</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Southern California College of Optometry at Marshall B. Ketchum University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The main objective of this randomized trial comparing vision therapy to observation is to&#xD;
      determine the short-term effectiveness of vision therapy on distance intermittent exotropia&#xD;
      control. The results will help determine whether to proceed to a full-scale, long-term&#xD;
      randomized trial.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Vision therapy (VT) is a commonly prescribed treatment for children with intermittent&#xD;
      exotropia (IXT). The effectiveness of VT as a treatment modality for children with IXT is&#xD;
      unknown because previous studies have largely limited observational or retrospective case&#xD;
      series without comparison groups. The objective of this multi-centered pilot randomized trial&#xD;
      of VT for IXT compared to observation is to 1) determine the short-term effectiveness of VT&#xD;
      on distance intermittent exotropia and 2) determine the feasibility of recruitment and&#xD;
      retention of children aged 8 to 16 years old with IXT to participate in a randomized trial of&#xD;
      20 weeks of in-office VT. The results of this trial will provide the needed information to&#xD;
      plan and conduct a large-scale randomized trial to determine short-term and long-term&#xD;
      effectiveness of VT for IXT in children, with the full-scale randomized trial helping to fill&#xD;
      in the gaps in scientific knowledge concerning VT as a treatment for IXT.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">May 2021</start_date>
  <completion_date type="Anticipated">May 2022</completion_date>
  <primary_completion_date type="Anticipated">May 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Mean Distance Control Score</measure>
    <time_frame>21 weeks</time_frame>
    <description>The primary analysis will be an intent-to-treat comparison of mean distance control score, determine by the intermittent exotropia office control scale, at outcome using an analysis of covariance model, which will adjust for baseline distance control. The intermittent exotropia office control scale grades the control on a scale of 0 (best control; phoria) to 5 (worst control; constant exotropia).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>No Spontaneous Tropia</measure>
    <time_frame>21 weeks</time_frame>
    <description>The proportion of participants with no spontaneous tropia at outcome will be compared between treatment groups.No spontaneous tropia is defined as control score of 2 or less on all three assessments of control at distance and near and no exotropia lasting more than 5 seconds throughout the examination.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Distance Control</measure>
    <time_frame>21 weeks</time_frame>
    <description>The proportion of participants with &gt;= 1 point change in control and &gt;= 2 points change in control will be compared between treatment groups.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Change in Vergence and Accommodative Measures</measure>
    <time_frame>21 weeks</time_frame>
    <description>The near point of convergence, positive and negative fusional vergence ranges at distance and near, vergence facility, accommodative amplitude, and accommodative facility at outcome will be compared between treatment groups adjusting for the corresponding baseline value. The analysis will be completed separately for each vergence and accommodative measures.</description>
  </other_outcome>
  <other_outcome>
    <measure>Suppression Status</measure>
    <time_frame>21 weeks</time_frame>
    <description>Suppression status will be compared at outcome between treatment groups, adjusting for baseline suppression status. Suppression status when the participant's eyes are in tropic position will be assessed using the suppression scale ranging from 0 (negligible suppression) to 4 (dense suppression).</description>
  </other_outcome>
  <other_outcome>
    <measure>Objective Eye Movement Recordings</measure>
    <time_frame>21 weeks</time_frame>
    <description>Frequency of intermittent exotropia by objective eye movement recordings will be compared between treatment groups.</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">58</enrollment>
  <condition>Intermittent Exotropia</condition>
  <arm_group>
    <arm_group_label>Vision Therapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive 20 consecutive weeks of office-based vision therapy with home therapy.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Observation</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Participants will receive no treatment for IXT is received during the study unless one of the deterioration criteria is met.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Vision Therapy</intervention_name>
    <description>20 consecutive weeks of office-based vision therapy with home therapy that aim to improve the participant's vergence skills, accommodative skills, and sensory fusion.</description>
    <arm_group_label>Vision Therapy</arm_group_label>
    <other_name>Orthoptics</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Major Inclusion Criteria-&#xD;
&#xD;
          -  Age 8 - 16 years&#xD;
&#xD;
          -  Intermittent exotropia meeting all of the following:&#xD;
&#xD;
               -  Distance exodeviation of 15∆ to 35∆ by prism alternating cover test (PACT)&#xD;
&#xD;
               -  IXT, exophoria, or orthophoria at near&#xD;
&#xD;
               -  Near exodeviation that does not exceed the distance exodeviation by more than 10∆&#xD;
&#xD;
               -  Mean distance control score of 2 points or more with at least one measure being 3&#xD;
                  points or higher&#xD;
&#xD;
               -  Mean near control score less than 5 points&#xD;
&#xD;
          -  Random dot stereopsis of 200&quot; or better on Preschool Randot Stereotest&#xD;
&#xD;
          -  Willingness to accept randomization and no plan to relocate in the next 6 months&#xD;
&#xD;
        Major Exclusion Criteria-&#xD;
&#xD;
          -  Treatment for IXT or amblyopia (other than refractive correction) within 3 months&#xD;
             prior to enrollment&#xD;
&#xD;
          -  Office-based vision therapy for IXT within 6 months prior to enrollment&#xD;
&#xD;
          -  Prior office-based vision therapy for IXT of ≥10 sessions&#xD;
&#xD;
          -  Prior strabismus, intraocular, or refractive surgery (including BOTOX injection)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>8 Years</minimum_age>
    <maximum_age>16 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Angela Chen, OD, MS</last_name>
    <role>Study Chair</role>
    <affiliation>Southern California College of Optometry at Marshall B. Ketchum University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Angela Chen, OD, MS</last_name>
    <phone>714-463-7569</phone>
    <email>angelachen@ketchum.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>University of Alabama in Birmingham</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35294</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>Kristine Hopkins, OD, MSPH</last_name>
      <phone>205-996-1678</phone>
      <email>kbhopkins@uab.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Southern California College of Optometry at Marshall B. Ketchum University</name>
      <address>
        <city>Fullerton</city>
        <state>California</state>
        <zip>92831</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>Angela Chen, OD, MS</last_name>
      <phone>714-463-7569</phone>
      <email>angelachen@ketchum.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Stanford University</name>
      <address>
        <city>Stanford</city>
        <state>California</state>
        <zip>94305</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>Tawna Roberts, OD, PhD</last_name>
      <phone>650-723-1143</phone>
      <email>tawnar@stanford.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Ohio State University</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43210</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>Ann Morrison, OD, MS</last_name>
      <phone>614-247-0010</phone>
      <email>morrison.421@osu.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Salus University</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19141</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>Erin Jenewein, OD, MS</last_name>
      <phone>215-276-6053</phone>
      <email>ejenewein@salus.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Southern College of Optometry</name>
      <address>
        <city>Memphis</city>
        <state>Tennessee</state>
        <zip>38104</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>Marie Bodack, OD</last_name>
      <phone>901-722-3349</phone>
      <email>mbodack@sco.edu</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>July 17, 2020</study_first_submitted>
  <study_first_submitted_qc>July 22, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">July 27, 2020</study_first_posted>
  <last_update_submitted>March 25, 2021</last_update_submitted>
  <last_update_submitted_qc>March 25, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 29, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Intermittent Exotropia</keyword>
  <keyword>Vision Therapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Exotropia</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

